Cytek Biosciences Delivers Record Q4 Revenue of $62.1M, Guides $205–212M for 2026
Cytek Biosciences reported Q4 2025 revenue of $62.1 million, up 8% year-over-year and its highest quarterly revenue, driven by double-digit growth in EMEA and APAC and a 208-unit installed-base expansion to 3,664 units. The company ended 2025 with $261.5 million cash, repurchased $15.1 million stock and set 2026 revenue guidance of $205–212 million.
1. Q4 Revenue Performance
Revenue in the fourth quarter rose to $62.1 million, an 8% increase year-over-year, led by double-digit service and instrument sales in EMEA and APAC. U.S. instrument revenue was flat with strength in academic and government segments, which grew 33%, and the installed base expanded by 208 units to 3,664, driving recurring revenue to 34% of sales.
2. Margins and Profitability
GAAP gross margin fell to 53% from 59% due to higher materials and overhead costs, and adjusted gross margin declined to 55%. Operating expenses climbed 25% to $38.5 million, the net loss widened to $44.1 million including a $38.1 million deferred tax valuation allowance, and adjusted EBITDA dropped to $5.0 million.
3. Balance Sheet and 2026 Guidance
The company closed 2025 with $261.5 million in cash and repurchased $15.1 million of stock. Management initiated 2026 revenue guidance of $205–212 million, citing expected U.S. and EMEA stabilization and continued service and reagent momentum.